Ofatumumab, an anti-CD20 therapy for multiple sclerosis, is associated with the rare but severe infectious complication of enteroviral encephalitis.
Case Report (n=1)
Is ofatumumab associated with enteroviral encephalitis in patients with multiple sclerosis?
Enteroviral encephalitis is a severe infectious complication associated with anti-CD20 therapies, including ofatumumab, as a class effect.
BACKGROUND: Enteroviral encephalitis is a rare but potentially devastating infectious complication described under the anti-CD20 therapies rituximab and ocrelizumab. CASE: A 37-year-old woman with multiple sclerosis (MS) on treatment with ofatumumab developed fever, confusion, seizures, and decreased level of consciousness. Magnetic resonance imaging (MRI) revealed bilateral, non-enhancing thalamic T2 hyperintensities, and cerebrospinal fluid showed pleocytosis with positive polymerase chain reaction (PCR) for enterovirus. The patient was treated with intravenous immunoglobulin and supportive care, and then pocapavir was given for ongoing neurologic deficits. She recovered over 6 weeks but continued to demonstrate neuropsychiatric symptoms. CONCLUSION: Enteroviral encephalitis is associated with anti-CD20 therapies for MS as a class effect including ofatumumab.
Rotstein et al. (Tue,) conducted a case report in Multiple sclerosis, enteroviral encephalitis (n=1). Ofatumumab was evaluated. Ofatumumab, an anti-CD20 therapy for multiple sclerosis, is associated with the rare but severe infectious complication of enteroviral encephalitis.